Equities analysts forecast that Marinus Pharmaceuticals Inc (NASDAQ:MRNS) will report earnings per share of ($0.23) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Marinus Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.20). Marinus Pharmaceuticals posted earnings per share of ($0.24) during the same quarter last year, which would suggest a positive year over year growth rate of 4.2%. The company is scheduled to report its next quarterly earnings results on Thursday, August 1st.
According to Zacks, analysts expect that Marinus Pharmaceuticals will report full year earnings of ($0.84) per share for the current financial year, with EPS estimates ranging from ($1.04) to ($0.55). For the next fiscal year, analysts expect that the firm will post earnings of ($0.86) per share, with EPS estimates ranging from ($1.25) to ($0.24). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Marinus Pharmaceuticals.
Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.03).
A number of institutional investors have recently made changes to their positions in MRNS. Wells Fargo & Company MN raised its position in Marinus Pharmaceuticals by 298.3% during the 3rd quarter. Wells Fargo & Company MN now owns 17,755 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 13,297 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Marinus Pharmaceuticals by 9.8% in the 3rd quarter. BlackRock Inc. now owns 2,910,405 shares of the biopharmaceutical company’s stock worth $29,103,000 after buying an additional 259,793 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of Marinus Pharmaceuticals during the 3rd quarter worth $544,000. MetLife Investment Advisors LLC purchased a new stake in shares of Marinus Pharmaceuticals during the 3rd quarter worth $292,000. Finally, Meeder Asset Management Inc. lifted its stake in shares of Marinus Pharmaceuticals by 1,082.4% during the 4th quarter. Meeder Asset Management Inc. now owns 10,819 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 9,904 shares during the last quarter. 65.39% of the stock is owned by hedge funds and other institutional investors.
NASDAQ MRNS traded down $0.18 during trading hours on Friday, reaching $4.61. The company’s stock had a trading volume of 36,498 shares, compared to its average volume of 710,276. The stock has a market capitalization of $242.28 million, a price-to-earnings ratio of -5.10 and a beta of 3.25. Marinus Pharmaceuticals has a 1-year low of $2.36 and a 1-year high of $10.54.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.